scholarly journals Chart Review Study to Evaluate Health Care Resource Utilization of Patients with Symptomatic Multiple Myeloma in the United Kingdom

2016 ◽  
Vol 19 (3) ◽  
pp. A156
Author(s):  
S Gonzalez-McQuire ◽  
K Yong ◽  
A Flinois ◽  
C Gazzola ◽  
P Schoen ◽  
...  
Keyword(s):  
Health Care ◽  
Multiple Myeloma ◽  
United Kingdom ◽  
Resource Utilization ◽  
Chart Review ◽  
Health Care Resource ◽  
Health Care Resource Utilization ◽  
The United Kingdom ◽  
Review Study

scholarly journals Retrospective Chart Review Study to Evaluate Health Care Resource Utilization in Patients with Symptomatic Multiple Myeloma in Italy

2016 ◽  
Vol 19 (3) ◽  
pp. A155-A156 ◽  
Author(s):  
S Gonzalez-McQuire ◽  
K Yong ◽  
A Flinois ◽  
C Gazzola ◽  
P Schoen ◽  
...  
Keyword(s):  
Health Care ◽  
Multiple Myeloma ◽  
Resource Utilization ◽  
Chart Review ◽  
Retrospective Chart Review ◽  
Health Care Resource ◽  
Health Care Resource Utilization ◽  
Review Study

scholarly journals Impact of Friedreich’s Ataxia on health-care resource utilization in the United Kingdom and Germany

2013 ◽  
Vol 8 (1) ◽  
pp. 38 ◽  
Author(s):  
Paola Giunti ◽  
Julia Greenfield ◽  
Alison J Stevenson ◽  
Michael H Parkinson ◽  
Jodie L Hartmann ◽  
...  
Keyword(s):  
Health Care ◽  
United Kingdom ◽  
Resource Utilization ◽  
Friedreich’S Ataxia ◽  
Health Care Resource ◽  
Friedreich's Ataxia ◽  
Health Care Resource Utilization ◽  
The United Kingdom

scholarly journals Health Care Resource Utilization and Costs among Adult Patients with Advanced Soft Tissue Sarcoma: A Retrospective Medical Record Review in the United Kingdom, Spain, Germany, and France

Sarcoma ◽  
2018 ◽  
Vol 2018 ◽  
pp. 1-13
Author(s):  
Daniel S. Mytelka ◽  
Saurabh P. Nagar ◽  
Yulia D’yachkova ◽  
Elizabeth M. La ◽  
James A. Kaye ◽  
...  
Keyword(s):  
Health Care ◽  
United Kingdom ◽  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Resource Utilization ◽  
Health Care Resource ◽  
Adult Patients ◽  
Advanced Soft Tissue Sarcoma ◽  
Health Care Resource Utilization ◽  
The United Kingdom

Objective. To describe health care resource utilization and costs for patients with advanced soft tissue sarcoma (STS) in the United Kingdom (UK), Spain, Germany, and France. Methods. Physicians abstracted data for adult patients with a diagnosis of advanced STS (other than Kaposi’s sarcoma or gastrointestinal stromal tumor) who received ≥1 lines of systemic therapy. Health care resource utilization related to advanced STS treatment was recorded; associated costs were estimated by applying unit costs. Results. A total of 130 physicians provided data for 807 patients (UK: 199; Spain: 203; Germany: 204; and France: 201). The site of care during active treatment varied based on differences in the health care systems of these four countries. Total mean per-patient health care cost in the UK was £19,457; in Spain, €26,814; in Germany, €20,468; and in France, €24,368. Advanced STS-related systemic treatment costs were driven primarily by drug acquisition and administration costs. Treatment-related costs increased during later lines of therapy for all countries except France, where they decreased after first-line therapy. Pain control and antiemetics were the most common supportive care medications. Conclusions. This study provides real-world data on resource utilization and estimated costs in advanced STS and could inform policymakers about treatment burden.

scholarly journals Treatment outcomes, health-care resource utilization and costs of bortezomib and dexamethasone, with cyclophosphamide or lenalidomide, in newly diagnosed multiple myeloma

Leukemia ◽  
2015 ◽  
Vol 30 (4) ◽  
pp. 995-998 ◽  
Author(s):  
S K Kumar ◽  
E Ma ◽  
A E Engebretson ◽  
F K Buadi ◽  
M Q Lacy ◽  
...  
Keyword(s):  
Health Care ◽  
Multiple Myeloma ◽  
Treatment Outcomes ◽  
Resource Utilization ◽  
Health Care Resource ◽  
Newly Diagnosed ◽  
Health Care Resource Utilization

Health care resource utilization (HCRU) in relapsed/refractory multiple myeloma (RRMM): Results from PREAMBLE.

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. 6621-6621 ◽  
Author(s):  
Hartmut Goldschmidt ◽  
Ravi Vij ◽  
David Kuter ◽  
David Cella ◽  
Teresa Maria Zyczynski ◽  
...  
Keyword(s):  
Health Care ◽  
Multiple Myeloma ◽  
Resource Utilization ◽  
Health Care Resource ◽  
Refractory Multiple Myeloma ◽  
Health Care Resource Utilization

scholarly journals Survival, health care resource utilization and expenditures of first-line treatments for multiple myeloma patients ineligible for transplant in Taiwan

PLoS ONE ◽  
2021 ◽  
Vol 16 (5) ◽  
pp. e0252124
Author(s):  
Chih-Ning Cheng ◽  
Shang-Yi Huang ◽  
Pei-Wen Lien ◽  
Shih-Ting Huang ◽  
Fang-Ju Lin
Keyword(s):  
Health Care ◽  
Multiple Myeloma ◽  
Resource Utilization ◽  
Real World ◽  
Health Care Resource ◽  
Real World Data ◽  
Health Care Resource Utilization ◽  
Outpatient Visits ◽  
World Information ◽  
One Year

Background We aimed to provide real-world information on survival, health care resource utilization (HCRU), and expenditures related to various first lines of therapy (1LOTs) in newly diagnosed multiple myeloma (NDMM) patients who were transplant ineligible (TI). Patients and methods From the Taiwan National Health Insurance Database (2008–2016), we identified 1,511 NDMM-TI patients who had received 1LOT since June 2012. We categorized 1LOT regimens into four groups: bortezomib (V)+thalidomide (T), V, T, and non-V/T. Patients’ characteristics were collected. The overall survival (OS), event-free survival (EFS), frequencies of HCRU (hospitalization, visiting outpatient and emergency departments), and related expenditures within one year after commencement of the 1LOT were evaluated and compared. Results The mean age of the included patients was 71.3 (SD 10.7) years, and 40.4% of patients had a CCI score ≥3. Most patients (747; 49.4%) were in the V+T group and, after adjusting for covariates, had a significantly longer OS (median, 22.2 months) and EFS (9.1 months) than those in the T group (12.6 and 4.5 months, respectively) and the non-V/T group (12.2 and 3.2 months, respectively), but they were mostly comparable with patients in the V group (23.8 and 6.6 months, respectively). Compared to those in the V+T group, patients in the T and non-V/T groups had 29% and 39% fewer outpatient visits and 15% and 24% lower total expenditure, respectively. Conclusion Our real-world data consolidate evidence for the effectiveness of bortezomib-containing regimens as the 1LOT in NDMM-TI patients at the expense of more outpatient visits and higher total costs.

Sign in / Sign up

Export Citation Format

Share Document